Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The update follows a European review of clinical evidence, post-authorisation reports and published literature, which concluded that semaglutide use in adults with type 2 diabetes may be associated with an approximately two-fold increase in the relative risk of developing NAION
For those with comorbid conditions like type 2 diabetes or hypertension, continuing on a maintenance dose of GLP-1 medication may help manage these conditions while also maintaining your weight loss
Lab work, reproductive goals, thyroid health, and lifestyle factors all influence the best approach
Safe Disposal Methods If your pharmacy or clinic has a medicine take-back program, just bring the pens or vials there
The most frequently reported weight loss category was 16 kg (37.5%), followed by 58 kg (24.7%), 912 kg (21.3%), 1315 kg (9.7%), and 14 kg (6.6%)
In assessment of the treatment effect, based on treatment adherence, results from STEP UP showed individuals treated with semaglutide 7.2 mg achieved a superior weight loss of 20.7% after 72 weeks, compared with 17.5% for semaglutide 2.4 mg and 2.4% for placebo
